Abstract:The prevalence of diabetes is increasing worldwide. Massive death of pancreatic beta-cells causes type 1 diabetes. Progressive loss of beta-cell function and mass characterizes type 2 diabetes. To date, none of the available antidiabetic drugs promotes the maintenance of a functional mass of endogenous beta-cells, revealing an unmet medical need. Dysfunction and apoptotic death of beta-cells occur, in particular, through the activation of intracellular protein kinases. In recent years, protein kinases have become highly studied targets of the pharmaceutical industry for drug development. A number of drugs that inhibit protein kinases have been approved for the treatment of cancers. The question of whether safe drugs that inhibit protein kinase activity can be developed and used to protect the function and survival of beta-cells in diabetes is still unresolved. This review presents arguments suggesting that several protein kinases in beta-cells may represent targets of interest for the development of drugs to treat diabetes.

What problem does this paper attempt to address?

The main problems that this paper attempts to solve are the dysfunction and death of pancreatic islet β - cells in diabetes. Specifically: 1. **Type 1 diabetes (T1D)**: T1D is characterized by a large number of pancreatic islet β - cell deaths due to autoimmune reactions. This process involves the infiltration of monocytes, leading to a high local concentration of pro - inflammatory cytokines and chemokines in the pancreatic islets. These factors induce apoptosis and dysfunction of β - cells by activating intracellular protein kinases (such as JNK, NF - κB, etc.). 2. **Type 2 diabetes (T2D)**: T2D is manifested as a gradual loss of β - cell function and quantity. Factors such as chronic hyperglycemia (glucotoxicity), certain high - concentration fatty acids (lipotoxicity), and islet amyloid polypeptide deposition, etc., cause mitochondrial dysfunction, oxidative stress, endoplasmic reticulum stress, etc. by activating intracellular stress kinases (such as JNK, p38 MAPK, etc.), and ultimately lead to β - cell dysfunction and apoptosis. 3. **Unmet medical needs**: Currently available antidiabetic drugs are still unable to promote the maintenance of the functional mass of endogenous β - cells, which reveals an unmet medical need. Therefore, the development of drugs that can protect the function and survival of β - cells has become the focus of research. 4. **Protein kinases as targets**: In recent years, protein kinases have become highly researched targets for drug development in the pharmaceutical industry. Some drugs that inhibit protein kinase activity have been approved for cancer treatment. However, whether safe and effective drugs can be designed and developed to inhibit protein kinase activity, thereby protecting the function and survival of β - cells in T1D and T2D, remains an unsolved problem. By reviewing existing research, the paper proposes that multiple protein kinases (such as MST1, TAK1, TPL2, c - Abl, TYK2, JAK1, GSK - 3β, etc.) may be potential targets for the development of drugs for treating diabetes, and discusses the mechanism of action of these kinases in β - cells and the research progress of their inhibitors.

Targeting Protein Kinases to Protect Beta-Cell Function and Survival in Diabetes

Receptors and Signaling Pathways Controlling Beta-Cell Function and Survival as Targets for Anti-Diabetic Therapeutic Strategies

The Role of G Protein-Coupled Receptors and Receptor Kinases in Pancreatic {beta}-Cell Function and Diabetes

Targeting the pancreatic β-cell to treat diabetes

Targeted Pharmacological Therapy Restores Beta-Cell Function For Diabetes Remission

Gene therapy targeting key beta cell regulators as a potential intervention for diabetes

Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus

Cellular Signaling Pathways Regulating Β‑cell Proliferation As a Promising Therapeutic Target in the Treatment of Diabetes (Review)

Are off-target effects of imatinib the key to improving beta-cell function in diabetes?

From Pancreatic β-Cell Gene Networks to Novel Therapies for Type 1 Diabetes

Advances in Drug Discovery for Human Beta Cell Regeneration

Harnessing beta cell regeneration biology for diabetes therapy

Regeneration of Pancreatic Beta Cells by Modulation of Molecular Targets Using Plant-Derived Compounds: Pharmacological Mechanisms and Clinical Potential

Targeting β-Cell Plasticity: A Promising Approach for Diabetes Treatment

Pancreatic -cell failure, clinical implications, and therapeutic strategies in type 2 diabetes

Pancreatic β-cell failure, clinical implications, and therapeutic strategies in type 2 diabetes

Pancreatic Beta Cell Regeneration Induced By Clinical And Preclinical Agents

Plant-Derived Compounds Targeting Pancreatic Beta Cells for the Treatment of Diabetes

Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers

Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus

Preservation of β-Cells as a Therapeutic Strategy for Diabetes